SMMT Stock Risk & Deep Value Analysis
Summit Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About SMMT Stock
We analyzed Summit Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran SMMT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
SMMT Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Negative HARMONi-3 clinical data
- 📅
PDUFA delay or complete response letter from FDA for BLA
- 📅
Continued uncertainty or negative update on China trial (HARMONi-2/HARMONi-6) overall survival data timing
Unlock SMMT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Summit Therapeutics Inc (SMMT) Do?
Market Cap
$14.35B
Sector
Healthcare
Industry
Biotechnology
Employees
159
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.
Visit Summit Therapeutics Inc WebsiteInvestment Thesis
Summit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it navigates the inherent execution and regulatory risks successfully.
Is SMMT Stock Undervalued?
Unlock the full AI analysis for SMMT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
SMMT Price Targets & Strategy
12-Month Target
$31.37
Bull Case
$41.53
Bear Case
$11.87
Valuation Basis
Based on median analyst price target reflecting anticipated progress towards regulatory approval and commercialization.
Entry Strategy
Consider dollar-cost averaging in the $15-$18 range, monitoring for positive catalyst news flow or dips towards previous support levels.
Exit Strategy
Initiate profit-taking at $30-$40, reassess after key regulatory approvals and commercial launch data. Stop loss below $11.87 (low analyst target).
Portfolio Allocation
7-15% for aggressive risk tolerance, given the high-risk, high-reward nature of clinical-stage biotech.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is SMMT Financially Healthy?
Valuation
P/E Ratio
-10.42
Price/Book
74.67
Profitability
Return on Equity
-292.49%
EPS
$-1.25
Balance Sheet
Debt/Equity
0.03
Total Debt
$5.43M
Cash & Equivalents
$238.55M
Cash Flow
Operating Cash Flow
-$269.67M
Free Cash Flow
-$270.17M
EBITDA
-$934.99M
Other
Beta (Volatility)
-1.43
Does SMMT Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat's durability hinges on the successful clinical development and regulatory approval of ivonescimab, which would grant market exclusivity through patent protection. Its differentiation as a bispecific antibody in a high-need area also strengthens its competitive position.
Moat Erosion Risks
- •Clinical trial failure or inability to achieve regulatory approval
- •Development of superior or similar competing therapies by rivals
- •Patent challenges or expiry, leading to generic competition
SMMT Competitive Moat Analysis
Sign up to see competitive advantages
SMMT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (no specific data provided, but generally optimistic given potential)
Institutional Sentiment
Positive, with 11 Buy ratings from 15 analysts, but recent Jefferies downgrade to Hold and H.C. Wainwright PT cut ($40 to $30) indicate increased caution.
Insider Activity (Form 4)
No Form 4 filings in the last 90 days. Earlier in 2025: Director Xia Yu bought 533,617 shares ($9.99M) on Oct 21, 2025; Co-CEO Mahkam bought 333,394 shares ($5.89M) on Sep 10, 2025; Co-CEO Duggan Robert W bought 5,000 shares ($90.3K) on Sep 11, 2025.
Options Flow
Normal options activity (no specific data provided).
Earnings Intelligence
Next Earnings
2026-05-07 (Q1 2026 estimate)
Surprise Probability
Medium
Historical Earnings Pattern
Historically, clinical-stage biotech stocks are highly sensitive to regulatory and clinical trial news rather than pure financial results. A Q4 2025 EPS miss was noted, and similar misses could cause short-term volatility.
Key Metrics to Watch
Competitive Position
Top Competitor
No specific direct peer for ivonescimab's bispecific mechanism in NSCLC provided, but large oncology players like Merck (Keytruda), Bristol-Myers Squibb (Opdivo), Roche (Tecentriq) are broader competitors in NSCLC.
Market Share Trend
Pre-commercial; currently has no market share but aims to capture a significant portion of the 2nd-line EGFR mutant NSCLC market post-approval.
Valuation vs Peers
Significantly overvalued, trading at a P/B of 18.7x compared to biotech peers at 9.9x and US biotechs at 2.6x.
Competitive Advantages
- •Differentiated bispecific antibody (PD-1/VEGF) mechanism for NSCLC
- •Potential first-mover advantage with this specific bispecific combination in US/EU
- •Robust clinical data from China trials (partnered with Akeso) supporting efficacy
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive SMMT Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Expected May 7)
- •HARMONi-3 Interim Data (Q2 2026)
- •PDUFA date for ivonesimab BLA acceptance (November 2026)
Medium-Term (6-18 months)
- •Potential FDA approval for ivonesimab (post-Nov 2026 PDUFA)
- •US/EU Commercial launch preparations for ivonesimab
- •Further clinical trial data for other indications (CRC, head/neck cancer)
Long-Term (18+ months)
- •Ivonescimab market penetration and leadership in 2nd-line NSCLC
- •Pipeline expansion and additional indications for ivonescimab
- •Establishment as a dominant oncology player
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for SMMT?
- ✓
Positive outcomes from HARMONi-3 interim data and China OS data releases
- ✓
FDA approval for ivonescimab following the BLA acceptance PDUFA date
- ✓
Updates on commercialization strategy and partnership expansions
Bull Case Analysis
See what could go right with Premium
Competing with SMMT
See how Summit Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Summit Therapeutics Inc SMMT | $14.3B | 8.7 | -10.4 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Summit Therapeutics Inc (SMMT)?
As of March 24, 2026, Summit Therapeutics Inc has a DVR Score of 8.7 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Summit Therapeutics Inc?
Summit Therapeutics Inc's market capitalization is approximately $14.3B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Summit Therapeutics Inc use?
SMMT is the ticker symbol for Summit Therapeutics Inc. The company trades on the NGM.
What is the risk level for SMMT stock?
Our analysis rates Summit Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of SMMT?
Summit Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -10.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Summit Therapeutics Inc's revenue growing?
Summit Therapeutics Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is SMMT stock profitable?
Summit Therapeutics Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the SMMT DVR analysis updated?
Our AI-powered analysis of Summit Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for SMMT (Summit Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.